Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Katie Schrack

Ophthalmology Bala Cynwyd, PA Medical Doctor

NPI 1427217207 CMS profile 109773

100 Presidential Blvd Ste 200, Bala Cynwyd, PA 19004

Open in the dashboard

General payments

$6,584

298 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Katie Schrack of Bala Cynwyd, PA is reported in the CMS Open Payments database as having received $6,584 across 298 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,291 64
2024 General $1,138 53
2023 General $891 48
2022 General $927 44
2021 General $860 42
2020 General $369 15
2019 General $1,108 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Katie Schrack
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Katie Schrack were reported at $1,291. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Katie Schrack Ophthalmology median Middle half National median
2019 $1,108 $258 $104–$655 $163
2020 $369 $126 $45–$321 $114
2021 $860 $205 $76–$534 $132
2022 $927 $266 $100–$678 $149
2023 $891 $308 $117–$745 $160
2024 $1,138 $340 $127–$846 $164
2025 $1,291 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alcon Vision LLC $1,330 31 payments
  2. Sun Pharmaceutical Industries Inc. $853 52 payments
  3. Novartis Pharmaceuticals Corporation $695 59 payments
  4. TissueTech, Inc. $620 25 payments
  5. Dompe US, Inc. $549 19 payments
  6. Oyster Point Pharma, Inc. $541 33 payments
  7. Tarsus Pharmaceuticals, Inc. $406 11 payments
  8. Allergan Inc. $325 10 payments
  9. Bausch & Lomb Americas Inc. $233 11 payments
  10. AbbVie, Inc. $190 10 payments
  11. Other $842 37 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,527 296 payments
  2. Education $40 1 payment
  3. Gift $17 1 payment
Products named General payments · program years 2019–2025
  1. Cequa $812 50 payments
  2. XIIDRA $588 58 payments
  3. Clareon $480 11 payments
  4. XDEMVY $406 11 payments
  5. TYRVAYA $366 24 payments
  6. OXERVATE $353 13 payments
  7. Ryzumvi $314 20 payments
  8. AmnioGuard $269 7 payments
  9. Prokera $269 7 payments
  10. AmnioGraft $269 7 payments
  11. Other $3,742 150 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

1,840

Median for Ophthalmology: 891

Drug cost

$701,912

Median for Ophthalmology: $68,233

Branded share of claims

46.4%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Restasis Cyclosporine Brand 208 $219,814
Xiidra Lifitegrast Brand 146 $183,336
Cyclosporine Generic 99 $61,040
Miebo Perfluorohexyloctane/Pf Brand 51 $45,832
Lumigan Bimatoprost Brand 61 $35,444
Cequa Cyclosporine Brand 22 $29,930
Xdemvy Lotilaner Brand 15 $27,541
Tyrvaya Varenicline Tartrate Brand 23 $20,159
Vyzulta Latanoprostene Bunod Brand 28 $12,628
Loteprednol Etabonate Generic 72 $12,258

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$322,809

Medicare's payments for the services billed

Medicare patients

1,506

Average age 77

Services billed

3,168

975 women, 531 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 46%
Ischemic heart disease 29%
Osteoporosis 26%
Diabetes 24%
Chronic kidney disease 19%
Cancer 19%
Atrial fibrillation 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Cequa
  • Sun Pharmaceutical Industries Inc. $215
$215 22 —
OXERVATE
  • Dompe US, Inc. $146
$146 — —
TYRVAYA
  • Oyster Point Pharma, Inc. $134
$134 23 —
XDEMVY
  • Tarsus Pharmaceuticals, Inc. $118
$118 15 —
VEVYE
  • Harrow Eye, LLC $44
$44 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

298 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record